Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
Department of Urology/Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Umeå University, Faculty of Medicine, Molecular Infection Medicine Sweden (MIMS). Umeå University, Faculty of Medicine, Department of Clinical Microbiology, Section of Virology.ORCID iD: 0000-0001-6553-0940
Umeå University, Faculty of Medicine, Department of Clinical Microbiology.
Department of Medical Sciences, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2021 (English)In: Trials, E-ISSN 1745-6215, Vol. 22, no 1, article id 209Article in journal, Letter (Refereed) Published
Abstract [en]

Objectives: The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observation that the majority of patients in need of intensive care are male, and the connection between androgen receptor signalling and expression of TMPRSS2, an enzyme important for SARS-CoV-2 host cell internalization.

Trial design: Hospitalised COVID-19 patients will be randomised (2:1) to enzalutamide plus standard of care vs. standard of care designed to identify superiority.

Participants: Included participants, men or women above 50 years of age, must be hospitalised for PCR confirmed COVID-19 symptoms and not in need of immediate mechanical ventilation. Major exclusion criteria are breast-feeding or pregnant women, hormonal treatment for prostate or breast cancer, treatment with immunosuppressive drugs, current symptomatic unstable cardiovascular disease (see Additional file 1 for further details). The trial is registered at Umeå University Hospital, Region Västerbotten, Sweden and 8 hospitals are approved for inclusion in Sweden.

Intervention and comparator: Patients randomised to the treatment arm will be treated orally with 160 mg (4x40 mg) enzalutamide (Xtandi®) daily, for five consecutive days. The study is not placebo controlled. The comparator is standard of care treatment for patients hospitalised with COVID-19.

Main outcomes: The primary endpoints of the study are (time to) need of mechanical ventilation or discharge from hospital as assessed by a clinical 7-point ordinal scale (up to 30 days after inclusion).

Randomisation: Randomisation was stratified by center and sex. Each strata was randomized separately with block size six with a 2:1 allocation ratio (enzalutamide + “standard of care”: “standard of care”). The randomisation list, with consecutive subject numbers, was generated by an independent statistician using the PROC PLAN procedure of SAS version 9.4 software (SAS Institute, Inc, Cary, North Carolina)

Blinding (masking): This is an open-label trial.

Numbers to be randomised (sample size): The trial is designed to have three phases. The first, an exploration phase of 45 participants (30 treatment and 15 control) will focus on safety and includes a more extensive laboratory assessment as well as more frequent safety evaluation. The second prolongation phase, includes the first 100 participants followed by an interim analysis to define the power of the study. The third phase is the continuation of the study up to maximum 600 participants included in total.

Trial Status: The current protocol version is COVIDENZA v2.0 as of September 10, 2020. Recruitment started July 29, 2020 and is presently in safety pause after the first exploration phase. Recruitment is anticipated to be complete by 31 December 2021.

Trial registrationEudract number 2020-002027-10

ClinicalTrials.gov Identifier: NCT04475601, registered June 8, 2020

Full protoco: lThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

Place, publisher, year, edition, pages
BioMed Central, 2021. Vol. 22, no 1, article id 209
Keywords [en]
androgen signalling, antiandrogen, COVID-19, enzalutamide, multicentre, protocol, Randomised controlled trial, TMPRSS2
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:umu:diva-181797DOI: 10.1186/s13063-021-05137-4ISI: 000629927400001Scopus ID: 2-s2.0-85102576066OAI: oai:DiVA.org:umu-181797DiVA, id: diva2:1541462
Available from: 2021-04-01 Created: 2021-04-01 Last updated: 2024-01-17Bibliographically approved

Open Access in DiVA

fulltext(416 kB)117 downloads
File information
File name FULLTEXT01.pdfFile size 416 kBChecksum SHA-512
fae6eb43ee895431f966f285e9a001624467b126c87e8f6d402da9af532ffe90800b277fbb1ad02fb5694ea31d8ac295420832226adf4947f3716e9205f3fe67
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Authority records

Överby, Anna K.Ahlm, ClasAngelin, MartinLindquist, ElisabethBuckland, RobertThellenberg-Karlsson, CamillaStyrke, JohanRepo, Johanna

Search in DiVA

By author/editor
Överby, Anna K.Ahlm, ClasAngelin, MartinLindquist, ElisabethBuckland, RobertThellenberg-Karlsson, CamillaStyrke, JohanRepo, JohannaJosefsson, Andreas
By organisation
Molecular Infection Medicine Sweden (MIMS)Section of VirologyDepartment of Clinical MicrobiologyWallenberg Centre for Molecular Medicine at Umeå University (WCMM)Urology and AndrologyOncology
In the same journal
Trials
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 117 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 504 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf